News

Neuroscientists Gary Lewin and James Poulet at the Max Delbrück Center for Molecular Medicine have won highly coveted and competitive ERC Advanced Grants to study pain and the neural mechanisms that underlie temperature perception.

The artists Elisabetta Citterio and Claudia Cagliano have created portraits of nearly 60 female researchers from nine countries. Twenty-five of them can be viewed in the "STEM Passion" exhibition until March 12, 2024 in the Rahel Hirsch Center for Translational Medicine Berlin.

Cell-based immunotherapies, particularly lab-produced immune cells known as CAR T cells, show promise in treating various cancers. But how do we produce effective ones? Gaetano Gargiulo from the Max Delbrück Center will develop a novel screening tool, supported by an ERC Proof of Concept Grant.

Diseases can emerge when the body’s production of serotonin is out of whack. Researchers led by Michael Bader from the Max Delbrück Center have discovered a therapeutic agent that brings down high levels of this hormone. Their start-up, Trypto Therapeutics, aims to develop the drug for the market.

After spending many years researching together, a group of scientists has founded CARTemis Therapeutics, a spin-off from the Max Delbrück Center. Uta Höpken, Armin Rehm, Anthea Wirges, and Mario Bunse want to use novel CAR T-cell therapies to help patients with cancers that are currently untreatable.

Whether aggressive cancer cells can spread unchecked depends, to no small degree, on their cellular neighborhood. Fabian Coscia wants to analyze exactly what happens at the proteome level during this interaction. He has now been selected for a €1 million-plus grant from the European Research Council (ERC) to pursue this research.

Cancer cells are capable of escaping chemotherapy and radiotherapy by activating a signaling pathway that prevents them from dying. Researchers led by Claus Scheidereit at the Max Delbrück Center have now described in Cell Chemical Biology two new compounds that block this escape route.

The stem cell therapy developed by MyoPax, a spin-off from the Max Delbrück Center and Charité, could soon be helping children with previously incurable muscle diseases thanks to an accelerated approval process. The necessary clinical trial will start in the fall.

While CAR-T cells have proven successful in treating certain types of leukemia and lymphoma, these immunotherapies can become even more effective. A clinical trial run by Charité and the Max Delbrück Center has been awarded a grant of several million euros to test a new approach.

Since the beginning of the COVID-19 pandemic, researchers have been working on mucosal vaccines that can be administered through the nose. Now, scientists in Berlin have developed a live attenuated vaccine for the nose. In “Nature Microbiology”, they describe the special immune protection it induces.